Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81

Cancer Research

Volumn 69, Issue 20, 2009, Pages 8102-8110

  Shin, Sook ^a   Kim, Tae Dong ^a   Fang, Jin ^b   Van Deursen, Jan M ^b   Dehm, Scott M ^c   Tindall, Donald J ^c   Grande, Joseph P ^b   Munz, Jan Marie ^b   Vasmatzis, George ^b   Janknecht, Ralf ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ETS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CARCINOGENESIS; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; FEMALE; GENETIC TRANSCRIPTION; MALE; MODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REPORTER GENE; SEMINAL VESICLE; TRANSGENIC MOUSE;

ANDROGENS; ANIMALS; BINDING SITES; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA-BINDING PROTEINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENHANCER ELEMENTS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPRECIPITATION; LASERS; LUCIFERASES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICRODISSECTION; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 70350228463     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0941     Document Type: Article

References (50)

1. Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006;12:1665-1671
2. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008;8:497-511.
3. Cai C, Hsieh CL, Omwancha J, et al. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol Endocrinol 2007;21: 1835-1846 (Pubitemid 47173795)
4. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007;448:595-599 (Pubitemid 47206938)
5. Hermans KG, van der Korput HA, van Marion R, et al. Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res 2008;68:7541-7549
6. Janknecht R. EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene 2005;363:1-14. (Pubitemid 41691887)
7. Benz CC, O'Hagan RC, Richter B, et al. HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 1997;15: 1513-1525 (Pubitemid 27464644)
8. Bosc DG, Goueli BS, Janknecht R. HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1. Oncogene 2001;20:6215-6224 (Pubitemid 32964434)
9. Goueli BS, Janknecht R. Upregulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol 2004;24: 25-35. (Pubitemid 38010032)
10. Shin S, Bosc DG, Ingle JN, Spelsberg TC, Janknecht R. Rcl is a novel ETV1/ER81 target gene upregulated in breast tumors. J Cell Biochem 2008;105:866-874
11. Signoretti S, Montironi R, Manola J, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000;92:1918-1925 (Pubitemid 32036922)
12. Osman I, Mikhail M, Shuch B, et al. Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J Urol 2005;174: 2174-2177 (Pubitemid 41611768)
13. Nishio Y, Yamada Y, Kokubo H, et al. Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology 2006;68:110-115 (Pubitemid 44037732)
14. Cheville JC, Karnes RJ, Therneau TM, et al. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol 2008;26:3930-3936
15. Kosari F, Munz JM, Savci-Heijink CD, et al. Identification of prognostic biomarkers for prostate cancer. Clin Cancer Res 2008;14:1734-1743
16. Zhang J, Thomas TZ, Kasper S, Matusik RJ. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo . Endocrinology 2000;141:4698-4710 (Pubitemid 32055150)
17. Fuchs B, Inwards CY, Janknecht R. Vascular endothelial growth factor expression is up-regulated by EWSETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin Cancer Res 2004;10:1344-1353 (Pubitemid 38365227)
18. Janknecht R. Analysis of the ERK-stimulated ETS transcription factor ER81. Mol Cell Biol 1996;16:1550-1556 (Pubitemid 26095626)
19. Goel A, Janknecht R. Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/ CAF, and HER2/Neu. Mol Cell Biol 2003;23:6243-6254 (Pubitemid 37013101)
20. Wu L, Matherly J, Smallwood A, et al. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther 2001;8:1416-1426 (Pubitemid 32895673)
21. Shin S, Janknecht R. Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D. Biochem Biophys Res Commun 2007;359:742-746 (Pubitemid 46901127)
22. Shin S, Rossow KL, Grande JP, Janknecht R. Involvement of RNA helicases p68 and p72 in colon cancer. Cancer Res 2007;67:7572-7578 (Pubitemid 47281348)
23. Goueli BS, Janknecht R. Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor. Oncogene 2003;22:8042-8047 (Pubitemid 37175868)
24. De Haro L, Janknecht R. Cloning of the murine ER71 gene (Etsrp71) and initial characterization of its promoter. Genomics 2005;85:493-502. (Pubitemid 40386478)
25. De Haro L, Janknecht R. Functional analysis of the transcription factor ER71 and its activation of the matrix metalloproteinase-1 promoter. Nucleic Acids Res 2002;30:2972-2979 (Pubitemid 34778157)
26. Kim TD, Shin S, Janknecht R. Repression of Smad3 activity by histone demethylase SMCX/JARID1C. Biochem Biophys Res Commun 2008;366:563-567 (Pubitemid 50012656)
27. Papoutsopoulou S, Janknecht R. Phosphorylation of ETS transcription factor ER81 in a complex with its coactivators CREB-binding protein and p300. Mol Cell Biol 2000;20:7300-7310
28. Knebel J, De Haro L, Janknecht R. Repression of transcription by TSGA/Jmjd1a, a novel interaction partner of the ETS protein ER71. J Cell Biochem 2006; 99:319-329 (Pubitemid 44297974)
29. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648 (Pubitemid 41528150)
30. Massie CE, Adryan B, Barbosa-Morais NL, et al. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 2007;8: 871-878 (Pubitemid 350001432)
31. Huang W, Shostak Y, Tarr P, Sawyers C, Carey M. Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J Biol Chem 1999;274:25756-25768 (Pubitemid 129530752)
32. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003;21:383-391
33. Wu J, Janknecht R. Regulation of the ETS transcription factor ER81 by the 90-kDa ribosomal S6 kinase 1 and protein kinase A. J Biol Chem 2002;277:42669-42679 (Pubitemid 35285636)
34. Janknecht R. Regulation of the ER81 transcription factor and its coactivators by mitogen- and stressactivated protein kinase 1 (MSK1). Oncogene 2003;22: 746-755 (Pubitemid 36269288)
35. Wang L, Liu B, Schmidt M, Lu Y, Wels W, Fan Z. Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells. Prostate 2001;47:21-28 (Pubitemid 32246749)
36. Louie MC, Yang HQ, Ma AH, et al. Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex. Proc Natl Acad Sci U S A 2003;100:2226-2230
37. Dowdy SC, Mariani A, Janknecht R. HER2/Neu- and TAK1-mediated up-regulation of the transforming growth factor h inhibitor Smad7 via the ETS protein ER81. J Biol Chem 2003;278:44377-44384 (Pubitemid 37377186)
38. Klezovitch O, Risk M, Coleman I, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A 2008;105:2105-2110
39. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008;10:177-188 (Pubitemid 351240884)
40. Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009;41: 619-624
41. King JC, Xu J, Wongvipat J, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009;41:524-526
42. Attard G, Clark J, Ambroisine L, et al. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer 2008;99:314-320
43. Ruizeveld de Winter JA, Trapman J, Vermey M, Mulder E, Zegers ND, van der Kwast TH. Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem Cytochem 1991;39: 927-936
44. Bostwick DG, Qian J, Bergstralh E, et al. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol 1996;155:1361-1367 (Pubitemid 26081240)
45. Wang L, Hricak H, Kattan MW, et al. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. Radiology 2007;242:182-188 (Pubitemid 44956023)
46. Gioeli D. Signal transduction in prostate cancer progression. Clin Sci (Lond) 2005;108:293-308. (Pubitemid 40516993)
47. Goel A, Janknecht R. Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. J Biol Chem 2004;279:14909-14916 (Pubitemid 38618881)
48. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen de AL, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res 2003;63:7638-7640 (Pubitemid 37466688)
49. Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 2001;85:1928-1936 (Pubitemid 34775331)
50. Zhou HJ, Yan J, Luo W, et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 2005;65:7976-7983 (Pubitemid 41297277)